Clinical Trial Update: Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a dendritic cell vaccine with or without cyclophosphamide for stage IV malignant melanoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Dendritic cell vaccine

Snippet

Sponsor: Baylor Research Institute | Conditions: Malignant Melanoma Stage IV | Phase 2 | Status: TERMINATED